P04 - Présentation des critères de substitution dans les publications d'essais contrôlés randomisés : élaboration et explication de l'extension CONSORT-Surrogate 2023

Laura Richert(Université de Bordeaux), R. Taylor(University of Oxford), Oriana Ciani(Bocconi University), Anthony Muchai Manyara(University of Bristol)

Journal of Epidemiology and Population Health

May 1, 2024

10.1016/j.jeph.2024.202444

Cited by 0

Related Papers

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

|The Lancet|2014|175

Sample size in multistakeholder Delphi surveys: at what minimum sample size do replicability of results stabilize?

|Journal of Clinical Epidemiology|2024|134

Recentralization within decentralization: County hospital autonomy under devolution in Kenya

|PLoS ONE|2017|104

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials

|EClinicalMedicine|2023|60

Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration

|BMJ|2024|45